In summary, the present study revealed the underlying mechanism by which darolutamide induces ferroptosis through the SREBP1-FASN axis in PCa, suggesting that the combination of darolutamide with FINs could be a promising therapeutic strategy for PCa patients with AR mutations. The gene discussed is SREBF1; the disease is posterior cortical atrophy.